03:12 , Jun 9, 2017 |  BC Week In Review  |  Financial News

Sirona Biochem completes C$587,000 private placement of convertible notes

On June 5, drug discovery company Sirona Biochem Corp. (TSX-V:SBM; Xetra:ZSB) raised C$587,000 ($435,554) in a private placement through the sale of 12% unsecured convertible notes which mature in 18 months and convert at C$0.18....
21:29 , May 4, 2017 |  BC Innovations  |  Tools & Techniques

Testing intelligence

An explosion in access to high-power hardware and deep computer learning has made companies like Atomwise Inc. confident that artificial intelligence (AI) can finally deliver on its decades-old promise to accelerate drug discovery. The company...
20:17 , Feb 10, 2017 |  BC Week In Review  |  Financial News

Sirona Biochem completes private placement of convertible notes

Endocrine/metabolic company Sirona Biochem Corp. (TSX-V:SBM; Xetra:ZSB) raised C$665,360 ($510,730) through the sale of convertible notes in a private placement on Feb. 3. The 18-month notes bear 12% interest and convert at C$0.18. Sirona Biochem...
15:50 , Feb 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Bladder cancer In vitro studies suggest inhibiting DNM2 could help treat metastatic bladder cancer. In a human bladder cancer cell line, a DNM2 inhibitor tool compound or siRNA targeting DNM2 decreased formation of invadopodia...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Sirona Biochem completes private placement of units

Sirona Biochem Corp. (TSX-V:SBM; OTCQX:SRBCF), Vancouver, B.C.   Business: Endocrine/Metabolic   Date completed: 2016-05-11   Type: Private placement of units   Raised: C$829,500 ($640,789)   Units: 4.1 million   Price: C$0.20 (unit)   Shares after...
08:00 , Dec 3, 2015 |  BC Innovations  |  Product R&D

Eyeing fewer needles

Eyevensys S.A.S. is creating a non-viral gene therapy platform for ophthalmic diseases that can deliver steady, low levels of therapeutic protein to the eye for up to a year with a single treatment. Having raised...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Affymetrix, Enzo microarrays news

Affymetrix paid Enzo $10 million to settle a patent infringement suit regarding Enzo’s U.S. Patent No. 7,064,197, covering a nucleic acid array, system and non-porous solid. Enzo filed the suit in 2012 in the U.S....
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

FlowScript HPV E6/E7 regulatory update

Enzo said the New York State Department of Health approved the company’s FlowScript HPV E6/E7 assay to detect HPV oncogenes E6 and E7. The company said the flow cytometry-based multiplex test will be available “in...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Enzo, Thermo Fisher genomics news

The U.S. Court of Appeals for the Federal Circuit (CAFC) vacated a lower court judgment that Life Technologies Corp .’s sequencing instruments infringed Enzo’s U.S. Patent No. 5,449,767, covering DNA sequencing compounds. The appeals court...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Enzo supply/service news

Enzo will pay $3.5 million to settle a case alleging that Enzo wrongfully input diagnosis codes into claim forms submitted to CMS for tests Enzo performed for physicians. The complaint was brought under the Federal...